Bio
Dr. Cedrik Britten has been serving as Chief Medical Officer of Immatics since 2020, where he leads the global clinical development of adoptive cell therapies and TCR Bispecifics pipeline from first-in-human studies through registration trials, including regulatory oversight. Previously, he was Vice President and Head of the Oncology Cell Therapy Research Unit at GlaxoSmithKline, where he built and led the company’s cell therapy strategy and end-to-end development capabilities. Prior to that, he served as Vice President of Research and Development at BioNTech RNA Pharmaceuticals. Dr. Britten holds an M.D. from Johannes Gutenberg University.